Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline

M. Nakane1, S. Takahashi*,1, I. Sekine2, I. Fukui3, M. Koizumi4, K. Kage2, Y. Ito1, K. Aiba1, N. Horikoshi1, K. Hatake1, Y. Ishikawa5 and E. Ogata2

1 Department of Medical Oncology, 2 Department of Internal Medicine, 3 Department of Urology, 4 Department of Radiology, 5 Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

*E-mail: stakahas@jfcr.or.jp

Malignant pheochromocytomas are rare, accounting for ~10% of all cases of pheochromocytoma. The prognosis is poor because of local recurrence or widespread metastasis [1]. To date, there has been no established chemotherapy for malignant pheochromocytoma. A conventional CVD regimen (consisting of cyclophosphamide, vincristine and dacarbazine) may reduce tumors, but remission is short [2]. Thus, attempts to devise other regimens are warranted in order to obtain a better outcome.

We report a 50-year-old Japanese male who had rapidly progressive malignant pheochromocytoma and was successfully treated with an ACVD regimen, anthracyclines plus CVD. The patient was diagnosed with left adrenal pheochromocytoma (4 x 3 cm) with increased catecholamine (CA) excretion levels and underwent adrenectomy in August 1990. He had become asymptomatic and CA excretion level dropped to normal after the surgery. Six years later, he presented with lower back pain, soaking sweats and right inguinal lymphadenopathy. CAs and their metabolites were elevated (Table 1). A CT (computed tomography) scan showed enlarged lymph nodes in the pelvic and para-aortic region. Biopsy specimens of the inguinal lymph node revealed relapse of the pheochromocytoma. Subsequently, the right inguinal lymph node enlarged from 2 to 10 cm in ~2 weeks, and the back pain was aggravated.


View this table:
[in this window]
[in a new window]
 
Table 1. Endocrinology data before and after ACVD chemotherapy
 
In February 1996, a combination chemotherapeutic regimen was initiated, consisting of doxorubicin 40 mg/m2 body surface area (BSA) on day 1, cyclophosphamide 750 mg/m2 BSA on day 1, vincristine 1.4 mg/m2 BSA on day 1 and dacarbazine 250 mg/m2 BSA on days 1–5, every 3–4 weeks. On the following day, the blood pressure dropped to 90/56 mm Hg. With i.v. hydration increased, his general condition improved within a few days. Symptoms were resolved over 2 weeks with normalization of CAs and their metabolites (Table 1). Since cardiovascular instability occurred, doxorubicin was replaced with epirubicin, which has lower cardiotoxicity, in the later chemotherapy. The patient was given 12 courses of ACVD combination chemotherapy, which led to a complete remission of the tumor and a biochemical response. Side-effects were grade 1 bone marrow suppression, nausea and hair loss. After February 1997, the consolidation CVD regimen was administered monthly for ~3 years. There has been no sign of recurrence for 3 years after the cessation of chemotherapy.

Considering their neural crest origin and biological similarities, the chemotherapeutic regimens for neuroblastoma could be promising candidates for malignant pheochromocytoma. The CVD regimen was based on the treatment for advanced neuroblastoma. This regimen has been reported to produce good responses in malignant pheochromocytoma, but the median duration of remission is 21 months [2]. For aggressive neuroblastoma, a combination chemotherapeutic regimen of cyclophosphamide, vincristine, dacarbazine and doxorubicin (CYVADIC) has been suggested to be more effective than doxorubicin alone or combination therapy without doxorubicin (CYVDIC) [3]. We achieved long-lasting complete remission using a ACVD regimen in a case with rapidly progressive disease.

To our knowledge, this is the first report of an anthracycline-containing combination chemotherapy for metastasized malignant pheochromocytoma. The ACVD regimen might be a feasible combination chemotherapy, with monitoring of the cardiovascular system; furthermore, it might improve response rates and lengthen disease-free survival.

M. Nakane1, S. Takahashi1*, I. Sekine2, I. Fukui3, M. Koizumi4, K. Kage2, Y. Ito1, K. Aiba1, N. Horikoshi1, K. Hatake1, Y. Ishikawa5 & E. Ogata2

1Department of Medical Oncology, 2Department of Internal Medicine, 3Department of Urology, 4Department of Radiology, 5Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan (*E-mail: stakahas@jfcr.or.jp)

References

1. van Heerden JA, Sheps SG, Hamberger B et al. Pheochromocytoma: current status and changing trends. Surgery 1982; 91: 367–373.[ISI][Medline]

2. Averbuch SD, Steakley CS, Young RC et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109: 267–273.[ISI][Medline]

3. Dosik GM, Rodriguez V, Benjamin RS, Bodey GP. Neuroblastoma in the adult: effective combination chemotherapy. Cancer 1978; 41: 56–63.[ISI][Medline]





This Article
Full Text (PDF)
E-letters: Submit a response
Alert me when this article is cited
Alert me when E-letters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Nakane, M.
Articles by Ogata, E.
PubMed
PubMed Citation
Articles by Nakane, M.
Articles by Ogata, E.